Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Clin Res Hepatol Gastroenterol
    June 2024
  1. L'HUILLIER R, Michoud C, Dumortier J, Milot L, et al
    Massive peritoneal tumoral dissemination after hepatocellular carcinoma percutaneous microwave ablation with intraperitoneal CO(2) insufflation.
    Clin Res Hepatol Gastroenterol. 2024;48:102376.
    >> Share

  2. ROGALSKI J, Czarnecka-Chrebelska K, Weglewska K, Pleska K, et al
    Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients.
    Clin Res Hepatol Gastroenterol. 2024;48:102366.
    >> Share

  3. ZHOU J, Liang T, Xing F, Li X, et al
    Probabilistic Scatter Plots for visualizing carbohydrate and lipid metabolism states in Non-Alcoholic Fatty Liver Disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102365.
    >> Share

  4. ZHAO G, Shi R, Ma M, Lin H, et al
    Elevated LDL-c may warn of the risk of gallbladder stones in the patients with metabolic dysfunction-associated steatotic liver disease: A case-control study.
    Clin Res Hepatol Gastroenterol. 2024;48:102363.
    >> Share

  5. MAREY MM, Belal M, Awad AA, Rabea EM, et al
    Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2024;48:102357.
    >> Share

  6. LEIDECK P, Nkontchou G, Elkrief L, Erard D, et al
    The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience.
    Clin Res Hepatol Gastroenterol. 2024;48:102355.
    >> Share

  7. TANAKA A, Corpechot C
    PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
    Clin Res Hepatol Gastroenterol. 2024;48:102358.
    >> Share

  8. ZHOU F, Liu X, Chang C, Liu J, et al
    Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102352.
    >> Share

  9. BOEKEN T
    Redefining challenging liver thermal ablation cases: Present realities, future prospects.
    Clin Res Hepatol Gastroenterol. 2024;48:102342.
    >> Share

  10. MENG X, Wang L, Du YC, Cheng D, et al
    PPARbeta/delta as a promising molecular drug target for liver diseases: A focused review.
    Clin Res Hepatol Gastroenterol. 2024;48:102343.
    >> Share

  11. PAN X, Hu E, Zhou Y, Li L, et al
    The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102344.
    >> Share

    May 2024
  12. MANSUR A, Grobman B, Lu CY
    Suicide risk is elevated among patients with chronic liver disease and cirrhosis in the United States.
    Clin Res Hepatol Gastroenterol. 2024;48:102378.
    >> Share

  13. ZHU X, Zeng C, Yu B
    White adipose tissue in metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102336.
    >> Share

  14. ABBASSI N, Bourrahouat A, Bedoya EC, Pagan C, et al
    Phenotype and molecular characterization of Wilson's disease in Morocco.
    Clin Res Hepatol Gastroenterol. 2024;48:102335.
    >> Share

  15. WONG SH, Ng HI, Liu Y, Yu HH, et al
    Endoscopic submucosal dissection for early esophageal squamous cell carcinoma after ligation and sclerotherapy of esophageal and gastric varices.
    Clin Res Hepatol Gastroenterol. 2024;48:102339.
    >> Share

  16. FULBERT M, El Amrani M, Baillet C, Lecolle K, et al
    Sarcopenia does not affect liver regeneration and postoperative course after a major hepatectomy. A prospective study on 125 patients using CT volumetry and HIDA scintigraphy.
    Clin Res Hepatol Gastroenterol. 2024;48:102332.
    >> Share

  17. LI R, Sarin S
    The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
    Clin Res Hepatol Gastroenterol. 2024;48:102323.
    >> Share

  18. LIANG Y, Li J, Zhang Z, Jiang T, et al
    Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.
    Clin Res Hepatol Gastroenterol. 2024;48:102321.
    >> Share

  19. CHANG G, Sun J, Li J, Li T, et al
    Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2024 May 1:102361.
    >> Share

    April 2024
  20. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
    Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
    Clin Res Hepatol Gastroenterol. 2024;48:102337.
    >> Share

  21. LI Y, Guo Y, Tan S
    Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102320.
    >> Share

  22. ORUC M, Gedik ME, Uner M, Ulug E, et al
    Effectiveness of metformin for the reversal of cold-ischemia-induced damage in hepatosteatosis.
    Clin Res Hepatol Gastroenterol. 2024;48:102314.
    >> Share

  23. JI J, Zhang Z, Hou Z, Qiu G, et al
    Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102313.
    >> Share

    March 2024
  24. NDHLOVU E, Zhang BX, Chen XP, Zhu P, et al
    Thermal ablation for hepatic tumors in high-risk locations.
    Clin Res Hepatol Gastroenterol. 2024;48:102300.
    >> Share

  25. LI B, Ren ZW, Zhang C, Yu XX, et al
    Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching.
    Clin Res Hepatol Gastroenterol. 2024;48:102298.
    >> Share

  26. RAN D, Xin C, Ma Y, Lu Y, et al
    Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components.
    Clin Res Hepatol Gastroenterol. 2024;48:102302.
    >> Share

  27. CHEN F, Chen C, Zhang Y, Jiang L, et al
    Bilateral optic atrophy in Wilson disease: A case report and literature review.
    Clin Res Hepatol Gastroenterol. 2024;48:102299.
    >> Share

  28. AN Y, Xia Y, Wang Z, Jin GZ, et al
    Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102289.
    >> Share

  29. HAYAT HMS, Naeem H
    Aspirin for non alcoholic fatty liver disease: Promising but inconclusive-A letter to the editor.
    Clin Res Hepatol Gastroenterol. 2024;48:102286.
    >> Share

  30. HOOSHMAND GHARABAGH L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A, et al
    Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102279.
    >> Share

    February 2024
  31. GUO J, Shi L, Sun Y
    Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102284.
    >> Share

  32. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    >> Share

  33. MEJAIT A, Roux C, Soret M, Larrey E, et al
    Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Clin Res Hepatol Gastroenterol. 2024;48:102282.
    >> Share

  34. QI X, Liu L
    The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features.
    Clin Res Hepatol Gastroenterol. 2024;48:102273.
    >> Share

  35. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    >> Share

  36. OBADIA MA, Woimant F, Tuppin P, Debray D, et al
    Reply to "Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the National health insurance database".
    Clin Res Hepatol Gastroenterol. 2024;48:102265.
    >> Share

    January 2024
  37. KUMAR J, Mohsin S, Hasan M, Bilal AR, et al
    Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102261.
    >> Share

  38. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    >> Share

  39. BAEK KW, Won JH, Xiang YY, Woo DK, et al
    Exercise intensity impacts the improvement of metabolic dysfunction-associated steatotic liver disease via variations of monoacylglycerol O-acyltransferase 1 expression.
    Clin Res Hepatol Gastroenterol. 2024;48:102263.
    >> Share

  40. CHEVAL M, Latrasse M, Tran Ba S, Robbe G, et al
    Extensive cortical and thalamic FLAIR hypersignals in a patient with suspected hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2024;48:102258.
    >> Share

  41. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    >> Share

    December 2023
  42. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    >> Share

  43. LASSAILLY G, Ningarhari M, Dumortier J, Lafforgue C, et al
    Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;48:102266.
    >> Share

  44. JIANG J, Hu Y, Fang D, Luo J, et al
    Glutamine synthetase and hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102248.
    >> Share

  45. ZHANG X, Li X, Xiong X
    Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Clin Res Hepatol Gastroenterol. 2023;47:102230.
    >> Share

  46. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    >> Share

  47. TAMILMANI P, Sathibabu Uddandrao VV, Chandrasekaran P, Saravanan G, et al
    Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-alpha/AMPK and Nrf-2/HO-1 signaling pathways.
    Clin Res Hepatol Gastroenterol. 2023;47:102231.
    >> Share

  48. PEI E, Wang H, Li Z, Xie X, et al
    Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102229.
    >> Share

  49. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    >> Share

  50. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    >> Share

    November 2023
  51. ALLAIRE M, Roux C, Akhavan S, Lebray P, et al
    Difficulties in assessing portal hypertension in case of HVB-HVD co infection.
    Clin Res Hepatol Gastroenterol. 2023;47:102213.
    >> Share

  52. MUTANEN A, Pakarinen MP
    Featuring molecular regulation of bile acid homeostasis in pediatric short bowel syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102220.
    >> Share

    October 2023
  53. DENG K, Yang F, Liu X, Deng M, et al
    Adult Kasabach-Merritt syndrome secondary to hepatic angiosarcoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102211.
    >> Share

  54. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    >> Share

  55. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    >> Share

  56. DI GIORGIO A, Sciveres M, Fuoti M, Sonzogni A, et al
    Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Clin Res Hepatol Gastroenterol. 2023;47:102185.
    >> Share

  57. BOILLOT O, Guillaud O, Wischlen E, Ruiz M, et al
    Determinants of early surgical complications after pediatric liver transplantation: A single center/single surgeon experience over 20 years.
    Clin Res Hepatol Gastroenterol. 2023;47:102222.
    >> Share

    August 2023
  58. LU M, Zhu M, Li H, Wang Q, et al
    Factors associated with discordance in the assessment of fibrosis stage between transient elastography and liver biopsy in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102183.
    >> Share

  59. TANG Y, Zhong H, Wang Y, Wu J, et al
    Efficacy of microwave ablation versus radiofrequency ablation in the treatment of colorectal liver metastases: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102182.
    >> Share

  60. MAMANDIPOOR B, Wernly S, Semmler G, Flamm M, et al
    Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study.
    Clin Res Hepatol Gastroenterol. 2023;47:102181.
    >> Share

  61. CALLERI A, Alessandria C
    Renal damage in Hepatorenal Syndrome: A still unsolved issue.
    Clin Res Hepatol Gastroenterol. 2023;47:102178.
    >> Share

  62. BANDYOPADHYAY S, Samajdar SS, Das S
    Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102174.
    >> Share

  63. GUO B, Zhou Y, Liu Z, Chen Q, et al
    TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.
    Clin Res Hepatol Gastroenterol. 2023;47:102169.
    >> Share

  64. PENA LC, Couto CA, Correa BHM, Ferrua LFQ, et al
    Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102163.
    >> Share

  65. LI ZX, Zhang QF, Huang JM, Huang SJ, et al
    Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102165.
    >> Share

  66. ISMAIEL A, Hosiny BE, Ismaiel M, Leucuta DC, et al
    Waist to height ratio in nonalcoholic fatty liver disease - Systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102160.
    >> Share

  67. WAN W, Zhang H, Ji T, Zhang L, et al
    Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study.
    Clin Res Hepatol Gastroenterol. 2023;47:102157.
    >> Share

  68. ALOYSIUS MM, Iskander P, Ahmed K, Asija U, et al
    Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data.
    Clin Res Hepatol Gastroenterol. 2023;47:102162.
    >> Share

  69. YANG Y, Li X, Zhao X, Liu Y, et al
    Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study.
    Clin Res Hepatol Gastroenterol. 2023;47:102150.
    >> Share

  70. LU Y, Liang L, Lu WF, Cheng J, et al
    The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102147.
    >> Share

  71. XU J, Shao R, Zhang X, Yao D, et al
    Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
    Clin Res Hepatol Gastroenterol. 2023;47:102149.
    >> Share

    June 2023
  72. WANG X, Xu GH, Yu J, Li H, et al
    When cirrhosis meets paroxysmal nocturnal hemoglobinuria: What kind of "fireworks" scenario will occur?
    Clin Res Hepatol Gastroenterol. 2023;47:102173.
    >> Share

  73. GIUDICELLI H, Roux C, Monsel A, Conti F, et al
    Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation.
    Clin Res Hepatol Gastroenterol. 2023 Jun 19:102167.
    >> Share

    May 2023
  74. WISCHLEN E, Laverdure N, Erard D, Rohmer B, et al
    Iterative antibody-induced bile salt export pump deficiency after successive liver transplantations successfully treated with plasmapheresis and rituximab.
    Clin Res Hepatol Gastroenterol. 2023;47:102139.
    >> Share

  75. MATHURIN P, de Zelicourt M, Laurendeau C, Dhaoui M, et al
    Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102124.
    >> Share

  76. RAVAIOLI F, Berger A, Farcau O, Colecchia A, et al
    Individual and population screening of varices needing treatment by a simple, safe and accurate test.
    Clin Res Hepatol Gastroenterol. 2023;47:102123.
    >> Share

  77. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    >> Share

  78. HAMEED I, Hayat J, Marsia S, Samad SA, et al
    Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102111.
    >> Share

  79. BARAKAT LA, Elsergany AR, Ghattas MH, Mahsoub N, et al
    Relationship between interferon-induced transmembrane protein 3 and matrix metalloproteinase-9 gene polymorphisms in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102110.
    >> Share

  80. LAZO-DE-LA-VEGA-MONROY ML, Preciado-Puga MD, Ruiz-Noa Y, Salum-Zertuche M, et al
    Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
    Clin Res Hepatol Gastroenterol. 2023;47:102137.
    >> Share

  81. MEURER A, Antoni C, Ebert MP, Trimborn A, et al
    Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid-case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102130.
    >> Share

    April 2023
  82. SASAKI M, Sato Y, Nakanuma Y
    An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2023;47:102106.
    >> Share

  83. DUAN Y, Hou X, Guo J, Li H, et al
    D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102096.
    >> Share

    March 2023
  84. HARING MPD, de Haas RJ, van Vilsteren FGI, Klaase JM, et al
    Variation in the management of benign liver tumors: A European survey and case vignette study.
    Clin Res Hepatol Gastroenterol. 2023;47:102094.
    >> Share

  85. CAO L, Qu N, Wang X, Chen L, et al
    The function of long non-coding RNA in non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102095.
    >> Share

    February 2023
  86. IANNONE G, Pompili E, Renzulli M, Caraceni P, et al
    A case of peri-stomal ectopic variceal bleeding in a patient with decompensated cirrhosis treated with TIPS placement.
    Clin Res Hepatol Gastroenterol. 2023 Feb 24:102098.
    >> Share

  87. JENVRIN A, Galletto-Pregliasco A, Audureau E, Pujals A, et al
    Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score-matched case-control analysis.
    Clin Res Hepatol Gastroenterol. 2023 Feb 18:102097.
    >> Share

  88. JI PT, Wang XY
    Clinical application study on miR-98-5p as a prognostic biomarker in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102077.
    >> Share

  89. ZHANG L, Zhang X, Li Q, Makamure J, et al
    Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.
    Clin Res Hepatol Gastroenterol. 2023;47:102071.
    >> Share

  90. XIONG W, Qian Z, Mao X, Li J, et al
    T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102070.
    >> Share

  91. MURALI AR, Prakash S, Sanchez AJ
    Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients().
    Clin Res Hepatol Gastroenterol. 2023;47:102066.
    >> Share

  92. ALLAIRE M, Manfredi S, Lerosey L, Ganne-Carrie N, et al
    Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
    Clin Res Hepatol Gastroenterol. 2023;47:102059.
    >> Share

  93. ASGARZDEH A, Habibzadeh S, Asghariazar V, Safarzadeh E, et al
    Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination.
    Clin Res Hepatol Gastroenterol. 2023;47:102028.
    >> Share

    January 2023
  94. BECCHETTI C, Lange NF, Delgado MG, Bronnimann MP, et al
    2D shear wave elastography of the rectus femoris muscle in patients with cirrhosis: feasibility and clinical findings. A pilot study.
    Clin Res Hepatol Gastroenterol. 2023 Jan 16:102080.
    >> Share

  95. LIU L, Sun S, Li X
    LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation.
    Clin Res Hepatol Gastroenterol. 2023;47:102067.
    >> Share

  96. TIAN H, Zhang K, Hui Z, Ren F, et al
    Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019.
    Clin Res Hepatol Gastroenterol. 2023;47:102068.
    >> Share

  97. DU F, Zhang L, Zhang Y, Fan H, et al
    Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102069.
    >> Share

  98. ZHANG P, Dong X, Zhang W, Wang S, et al
    Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102063.
    >> Share

  99. HU L, Zheng Y, Lin J, Shi X, et al
    Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102061.
    >> Share

  100. WANG M, Sun L, Han X, Ren J, et al
    The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Clin Res Hepatol Gastroenterol. 2023;47:102060.
    >> Share

  101. YANG Y, Wang Y, Wang C, Wu S, et al
    Macrophages and derived-TNF-alpha promote lipopolysaccharide-induced upregulation of endogenous beta-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation.
    Clin Res Hepatol Gastroenterol. 2023;47:102062.
    >> Share

  102. OKADA S, Kashima K, Okada K, Okada J, et al
    Aging affects FIB-4 index in the general population without pre-existing diseases: Analysis of a cohort of healthy individuals who underwent annual health checkups for 10 consecutive years.
    Clin Res Hepatol Gastroenterol. 2023;47:102058.
    >> Share

  103. ZOU CY, Sun Y, Liang J
    Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis(,).
    Clin Res Hepatol Gastroenterol. 2023;47:102053.
    >> Share

  104. YANG XS, Li XH, Yan CY, Wei JP, et al
    Different 18F-FDG imaging: A rare case of liver multiple carcinomas.
    Clin Res Hepatol Gastroenterol. 2023;47:102050.
    >> Share

    December 2022
  105. LUO QQ, Wang T, Zhang KH
    New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:102043.
    >> Share

  106. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence.
    Clin Res Hepatol Gastroenterol. 2022;46:102034.
    >> Share

  107. SU Y, Xie R, Xu Q
    LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation.
    Clin Res Hepatol Gastroenterol. 2022;46:102025.
    >> Share

  108. MOHAMED MMG, Osman A, El-Halawany H
    Plasma exchange for patients with acute or acute on chronic liver failure; meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:102014.
    >> Share

  109. ZHANG X, Song W, Zhang M, Song Y, et al
    Identification of differentially expressed miRNAs and key genes involved in the progression of alcoholic fatty liver disease using rat models.
    Clin Res Hepatol Gastroenterol. 2022;46:102012.
    >> Share

  110. ZHAO E, Chen S
    Association of serum C-peptide with all-cause and cardiovascular disease mortality in ultrasound-defined nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:102002.
    >> Share

  111. DANIEL-ROBIN T, Benichou B, Leboucher C, Blein C, et al
    Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database.
    Clin Res Hepatol Gastroenterol. 2022;46:101992.
    >> Share

  112. LIU T, Yuan Z, Wang H, Wang J, et al
    Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.
    Clin Res Hepatol Gastroenterol. 2022;46:101835.
    >> Share

    November 2022
  113. LI N, Yang P, Fang J
    Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:102022.
    >> Share

  114. WASUWANICH P, Choudry H, So JM, Lowry S, et al
    Vanishing bile duct syndrome after drug-induced liver injury.
    Clin Res Hepatol Gastroenterol. 2022;46:102015.
    >> Share

  115. SHARMA D, Mandal P
    NAFLD: genetics and its clinical implications.
    Clin Res Hepatol Gastroenterol. 2022;46:102003.
    >> Share

  116. WU L, Yang J, Ke RS, Liu Y, et al
    Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101999.
    >> Share

  117. ISSA Z, Gohy S, Zech F, Baldin P, et al
    Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101977.
    >> Share

  118. FANG Z, Yang H, Mao Y
    Letter to the editor: Liver transarterial chemoembolization plus sunitinib for unresectable hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101984.
    >> Share

  119. GUILLAUD O, Woimant F, Couchonnal E, Dumortier J, et al
    Maintenance therapy simplification using a single daily dose: A preliminary real-life feasibility study in patients with Wilson disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101978.
    >> Share

    October 2022
  120. WANG J, Lun W, Shi W
    Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.
    Clin Res Hepatol Gastroenterol. 2022;46:102013.
    >> Share

  121. QIU JJ, Wei GF, Du JL, Guo J, et al
    Advances in the application of different anesthetic methods and drugs in interventional therapy for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101982.
    >> Share

  122. STEENSIG K, Pareek M, Krarup AL, Sogaard P, et al
    Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101952.
    >> Share

  123. DING Y, Jiang L, Wang Q, Zhao W, et al
    The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
    Clin Res Hepatol Gastroenterol. 2022;46:101951.
    >> Share

  124. BOGOVIC N, Doenecke A, Hart C, Lurken L, et al
    Covid19 vaccination-associated portal vein thrombosis-An interdisciplinary clinical challenge.
    Clin Res Hepatol Gastroenterol. 2022;46:101932.
    >> Share

  125. JAIN A, Sobotka LA, Wellner MR
    A rare mimicker of hepatocellular carcinoma: Syphilis.
    Clin Res Hepatol Gastroenterol. 2022;46:101919.
    >> Share

  126. BRAN DM, Fuks D, Lansier A, Gallois C, et al
    Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
    Clin Res Hepatol Gastroenterol. 2022;46:101920.
    >> Share

  127. THABUT D, Weil D, Bouzbib C, Rudler M, et al
    Non-invasive diagnosis and follow-up of portal hypertension.
    Clin Res Hepatol Gastroenterol. 2022;46:101767.
    >> Share

    August 2022
  128. SOURIANARAYANANE A, McCullough AJ
    Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101997.
    >> Share

  129. SHI Q, Wang F, Du N, Zhou Y, et al
    Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study.
    Clin Res Hepatol Gastroenterol. 2022;46:101986.
    >> Share

  130. SALTEL F, Blanc JF
    Hepatocellular carcinoma treatments: A new hope, but a headache for clinicians and researchers.
    Clin Res Hepatol Gastroenterol. 2022;46:101927.
    >> Share

  131. CHEN SQ, He K, Xiao XL
    Multifocal nodular fatty infiltration of the liver: A donut-shaped appearance.
    Clin Res Hepatol Gastroenterol. 2022;46:101985.
    >> Share

  132. DIAS E, Cardoso H, Pacheco J, Lopes J, et al
    Ciliated hepatic foregut cyst: An uncommon cystic liver lesion.
    Clin Res Hepatol Gastroenterol. 2022;46:101949.
    >> Share

  133. ZAFAR Y, Rashid AM, Siddiqi AK, Ellahi A, et al
    Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101970.
    >> Share

  134. CALES P, Ravaioli F, Berger A, Farcau O, et al
    Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.
    Clin Res Hepatol Gastroenterol. 2022;46:101925.
    >> Share

    June 2022
  135. NAYAGAM JS, Mandour MO, Taylor A, Heneghan MA, et al
    Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.
    Clin Res Hepatol Gastroenterol. 2022 Jun 18:101980.
    >> Share

  136. ADDEO P, Foguenne M, Michard B, Artzner T, et al
    Emergency reversal of a Roux-en-Y Gastric bypass to rescue liver graft from recurrent steatohepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101971.
    >> Share

  137. CHOU TP, Hu JT, Hung CS, Chen HY, et al
    Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
    Clin Res Hepatol Gastroenterol. 2022;46:101931.
    >> Share

  138. BARBIER L, Cauchy F
    What assessment of the liver before resection for hepatocellular carcinoma?
    Clin Res Hepatol Gastroenterol. 2022;46:101916.
    >> Share

  139. LIU X, Luo J, Zhang L, Yang F, et al
    SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2022;46:101897.
    >> Share

  140. WANG H, Liu D, Wang C, Yu S, et al
    Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
    Clin Res Hepatol Gastroenterol. 2022;46:101869.
    >> Share

    May 2022
  141. MOREIRA-SILVA H, Amorim J, Santos-Silva E
    Incidental Liver Lesions in children: A practical and evidence-based approach.
    Clin Res Hepatol Gastroenterol. 2022;46:101904.
    >> Share

  142. ELGENIDY A, Afifi AM, Awad AK, Jalal PK, et al
    Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101909.
    >> Share

  143. SHI Q, Liu J, Li T, Zhou C, et al
    Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101893.
    >> Share

  144. BOULOUTA A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, et al
    The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.
    Clin Res Hepatol Gastroenterol. 2022;46:101896.
    >> Share

  145. TRIPON S, Bilbault P, Fabacher T, Lefebvre N, et al
    Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101894.
    >> Share

  146. YOU Y, Hu S
    Aberrant expression of the esophageal carcinoma related gene 4 as a prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101891.
    >> Share

  147. ZHAO Y, Zhang C, Zhang Y, Bo C, et al
    Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101889.
    >> Share

    April 2022
  148. BOILLOT O, Chopinet S, Gregoire E, Milot L, et al
    Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: a case control comparative study.
    Clin Res Hepatol Gastroenterol. 2022 Apr 21:101929.
    >> Share

  149. WARASNHE K, Ozcay F, Aydin HI, Ozgun G, et al
    A Novel Mutation in TRMT5 Associated with Idiopathic Non-Cirrhotic Portal Hypertension and Hepatopulmonary Syndrome: Case Report of Two Siblings.
    Clin Res Hepatol Gastroenterol. 2022 Apr 20:101928.
    >> Share

  150. SUN L, Deng C, Gu Y, He Y, et al
    Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:101876.
    >> Share

  151. ZHANG X, Jiang M, Zhang X, Zhang J, et al
    An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101877.
    >> Share

  152. JAIN A, Kirkpatrick RB, Sobotka LA
    Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
    Clin Res Hepatol Gastroenterol. 2022;46:101875.
    >> Share

  153. LI L, Xin Y, Zhang X, Chen Y, et al
    The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2022;46:101878.
    >> Share

  154. HOORNAERT E, Yombi JC, Coubeau L, Baldin P, et al
    Liver hypodense infectious lesions: Is it only bacteria, parasites or fungi?
    Clin Res Hepatol Gastroenterol. 2022;46:101872.
    >> Share

  155. WASUWANICH P, So JM, Scheimann AO, Spahic H, et al
    Hepatic and non-hepatic hydrothorax in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2022;46:101868.
    >> Share

  156. ARTRU F, Moschouri E, Denys A
    Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
    Clin Res Hepatol Gastroenterol. 2022;46:101858.
    >> Share

  157. WANG H, He X, Fang D, Wang X, et al
    Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Clin Res Hepatol Gastroenterol. 2022;46:101853.
    >> Share

  158. ZHANG S, Zhao Y, He L, Bo C, et al
    Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101851.
    >> Share

  159. CANIVET CM, Smati S, Lannes A, Brisseau J, et al
    Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
    Clin Res Hepatol Gastroenterol. 2022;46:101848.
    >> Share

  160. ZHU X, Lin X, Zhang P, Liu Y, et al
    Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study.
    Clin Res Hepatol Gastroenterol. 2022;46:101843.
    >> Share

  161. ATHYROS VG, Katsiki N, Mikhailidis DP
    Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101842.
    >> Share

  162. ZHANG C, Zhang B, Chen A, Yin Q, et al
    Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-beta-mediated fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101833.
    >> Share

  163. SHAHID A, Cheema HA
    Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2022;46:101826.
    >> Share

  164. LYU T, Yao H, Wang J, Song L, et al
    Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Clin Res Hepatol Gastroenterol. 2022;46:101819.
    >> Share

  165. FATIMA K, Moeed A, Waqar E, Atif AR, et al
    Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101816.
    >> Share

  166. LONCAR Y, Tartrat N, Lastennet D, Lemoine L, et al
    Pulmonary infection after hepatic resection: Associated factors and impact on outcomes.
    Clin Res Hepatol Gastroenterol. 2022;46:101733.
    >> Share

    March 2022
  167. CORDEIRO A, Ribamar A, Ramalho A
    Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101807.
    >> Share

  168. JU S, Wang W, Chen P, Li F, et al
    Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Clin Res Hepatol Gastroenterol. 2022;46:101859.
    >> Share

  169. DUMORTIER J, Simon M, Bouhour F
    Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101854.
    >> Share

  170. DANA J, Girard M, Franchi-Abella S, Berteloot L, et al
    Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101855.
    >> Share

  171. LI J, Huang WF, Zhang JY
    A rare case of duodenal neuroendocrine tumor with hepatic metastasis.
    Clin Res Hepatol Gastroenterol. 2022;46:101850.
    >> Share

  172. TANG J, Chen C, Zhou M, Wang J, et al
    NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101847.
    >> Share

  173. VALTIS YK, Barlowe T, Young JH, Lichtman AH, et al
    A woman presenting with an unusual cause of fulminant liver failure and sepsis.
    Clin Res Hepatol Gastroenterol. 2022;46:101836.
    >> Share

  174. WU D, Zhang R, Zhan L
    Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile.
    Clin Res Hepatol Gastroenterol. 2022;46:101812.
    >> Share

  175. TANG J, Huang Z, Xu J, Lv Q, et al
    Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Clin Res Hepatol Gastroenterol. 2022;46:101814.
    >> Share

  176. SCHAEFER A, Journaux M, Mourabit HE, Mouri S, et al
    A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2022;46:101801.
    >> Share

  177. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
    Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
    Clin Res Hepatol Gastroenterol. 2022;46:101800.
    >> Share

  178. CAI Y, Wu D, Zhan L
    CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101796.
    >> Share

  179. PAPAEFTHYMIOU A, Koffas A, Laskaratos FM, Epstein O, et al
    Upper gastrointestinal video capsule endoscopy: The state of the art.
    Clin Res Hepatol Gastroenterol. 2022;46:101798.
    >> Share

    February 2022
  180. THOMAS LS, Geoffroy V, Patrick C, Rodolphe A, et al
    Infectious complications of portal biliopathy leading to liver transplantation.
    Clin Res Hepatol Gastroenterol. 2022 Feb 10:101879.
    >> Share

  181. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2022 Feb 3:101873.
    >> Share

  182. DU M, Yang S, Liu M, Liu J, et al
    COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
    Clin Res Hepatol Gastroenterol. 2022;46:101793.
    >> Share

  183. MACEDO MB, Giardini HAM, Pereira RMR
    A retracted diagnosis-when liver capsule retraction is not what it seems.
    Clin Res Hepatol Gastroenterol. 2022;46:101823.
    >> Share

  184. VITELLIUS C, Paisant A, Lannes A, Chaigneau J, et al
    Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses.
    Clin Res Hepatol Gastroenterol. 2022;46:101797.
    >> Share

  185. HE S, Chen W, Yang Y, Tang X, et al
    Adult diffuse hepatic hemangiomatosis: A case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2022;46:101789.
    >> Share

  186. WANG L, Peng Y, Qian Y, Liu Z, et al
    Transjugular extrahepatic portosystemic shunt (TEPS) creation in patients with complete occlusion of portal vein: Primary experience in a single medical center.
    Clin Res Hepatol Gastroenterol. 2022;46:101786.
    >> Share

  187. CAMPION B, Larrey E, Wagner M, Rudler M, et al
    Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage a trois" !
    Clin Res Hepatol Gastroenterol. 2022;46:101785.
    >> Share

  188. HUANG L, Liu J, Bie C, Liu H, et al
    Advances in cell death - related signaling pathways in acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2022;46:101783.
    >> Share

  189. LI Q, Xu H, Sui C, Zhang H, et al
    Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
    Clin Res Hepatol Gastroenterol. 2022;46:101781.
    >> Share

    January 2022
  190. XIN H, Zhang C, Ding Z, Zhang M, et al
    TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
    Clin Res Hepatol Gastroenterol. 2022;46:101777.
    >> Share

  191. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
    Non-invasive diagnosis and follow-up of benign liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101765.
    >> Share

  192. DE LEDINGHEN V
    Non-invasive diagnosis and follow-up of chronic liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101763.
    >> Share

  193. NAHON P, Aube C, Moga L, Chalaye J, et al
    Non-invasive diagnosis and follow-up of primary malignant liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101766.
    >> Share

  194. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
    Non-invasive diagnosis and follow-up of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101770.
    >> Share

  195. BOURSIER J, Guillaume M, Bouzbib C, Lannes A, et al
    Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101769.
    >> Share

  196. RAUTOU PE, Elkrief L, Decraecker M, Ollivier-Hourmand I, et al
    Non-invasive diagnosis and follow-up of vascular liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101764.
    >> Share

  197. SOBESKY R, Guillaud O, Bouzbib C, Sogni P, et al
    Non-invasive diagnosis and follow-up of rare genetic liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101768.
    >> Share

  198. BOURSIER J, Decraecker M, Bourliere M, Bureau C, et al
    Quality criteria for the measurement of liver stiffness.
    Clin Res Hepatol Gastroenterol. 2022;46:101761.
    >> Share

  199. CHEN BR, Pan CQ
    Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101755.
    >> Share

  200. STEMPAK-DROISSART T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al
    Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.
    Clin Res Hepatol Gastroenterol. 2022;46:101756.
    >> Share

  201. HOUNTONDJI L, Debourdeau A, Meunier L
    Acute liver failure secondary to Langerhans cell histiocytosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101744.
    >> Share

  202. ZIMMER V, Emrich K
    Nodular gastric antral vascular ectasia: Distinct portal hypertensive hyperplastic polyp lesions.
    Clin Res Hepatol Gastroenterol. 2022;46:101745.
    >> Share

  203. DU J, Zhang J, Chen X, Zhang S, et al
    Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101697.
    >> Share

    December 2021
  204. BORIE F, Dubray V, Tretarre B
    Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.
    Clin Res Hepatol Gastroenterol. 2021 Dec 25:101856.
    >> Share

    November 2021
  205. SOBOTKA LA, Mumtaz K, Hinton A, Conteh LF, et al
    The Time to Advocate for Influenza Vaccines in Patients with Cirrhosis is Now.
    Clin Res Hepatol Gastroenterol. 2021 Nov 20:101838.
    >> Share

  206. MOREIRA JLS, Barbosa SMB, Goncalves Junior J
    Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review.
    Clin Res Hepatol Gastroenterol. 2021;45:101752.
    >> Share

  207. THOEN RU, Longo L, Neto SC, Alvares-da-Silva MR, et al
    Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101638.
    >> Share

  208. RUTHER DF, Sebode M, Lohse AW, Wernicke S, et al
    Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER.
    Clin Res Hepatol Gastroenterol. 2021;45:101760.
    >> Share

  209. TUTUNCHI H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, et al
    Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
    Clin Res Hepatol Gastroenterol. 2021;45:101754.
    >> Share

  210. ZHAO J, Wang Y, Su H, Su L, et al
    Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101736.
    >> Share

  211. BLAISE L, Pereira H, Vilgrain V, Sutter O, et al
    Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
    Clin Res Hepatol Gastroenterol. 2021;45:101731.
    >> Share

  212. WONG YJ, Kew GS, Tan PS, Chen Z, et al
    Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study.
    Clin Res Hepatol Gastroenterol. 2021;45:101598.
    >> Share

  213. MOTAMED N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, et al
    The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study.
    Clin Res Hepatol Gastroenterol. 2021;45:101567.
    >> Share

  214. BOUZBIB C, Cluzel P, Sultanik P, Bernard-Chabert B, et al
    Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
    Clin Res Hepatol Gastroenterol. 2021;45:101593.
    >> Share

  215. HOU H, Chen D, Liu J, Feng L, et al
    Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
    Clin Res Hepatol Gastroenterol. 2021;45:101623.
    >> Share

  216. GE J, Zhang X, Zhang B, Zhu L, et al
    Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101573.
    >> Share

  217. LI X, Yu Y, Liu L
    Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101545.
    >> Share

  218. VEYRE F, Dumortier J, Radenne S, Valette PJ, et al
    Rare isolated spontaneous hepatic artery thrombosis in a non-transplant patient.
    Clin Res Hepatol Gastroenterol. 2021;45:101453.
    >> Share

  219. VANDE BERG P, Borbath I, Baldin P, Vande Berg D, et al
    Granuloma formation within perihepatic lymphadenopathy.
    Clin Res Hepatol Gastroenterol. 2021;45:101504.
    >> Share

  220. ABDI SAH, Shukla S, Khan J, Al Zahrani A, et al
    Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101443.
    >> Share

    October 2021
  221. ZHANG L, Zhou Y, Zhang J
    An incidental hepatic lesion in a cirrhotic liver.
    Clin Res Hepatol Gastroenterol. 2021 Oct 28:101825.
    >> Share

  222. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
    Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
    Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
    >> Share

  223. ARTZNER T, Legeai C, Antoine C, Jasseron C, et al
    Liver transplantation for critically ill cirrhotic patients: results from the French transplant registry.
    Clin Res Hepatol Gastroenterol. 2021 Oct 1:101817.
    >> Share

    September 2021
  224. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
    Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101556.
    >> Share

  225. MALEZIEUX E, Meunier L, Riviere B, Larrey D, et al
    Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI.
    Clin Res Hepatol Gastroenterol. 2021;45:101599.
    >> Share

  226. CHEN S, Zhao E
    Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101587.
    >> Share

  227. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
    Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101751.
    >> Share

  228. WAHLIN S, Andersson J
    Liver health literacy and social stigma of liver disease: A general population e-survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101750.
    >> Share

  229. LI X, Yao Q, Li R, Jin Y, et al
    Isoflurane induces liver injury by modulating the expression of miR-125a-5p.
    Clin Res Hepatol Gastroenterol. 2021;45:101732.
    >> Share

  230. BENARD J, Lafrance MJ, Gordien E, Amaral L, et al
    Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
    Clin Res Hepatol Gastroenterol. 2021;45:101706.
    >> Share

  231. YANG M, Wei S, Zhao H, Zhou D, et al
    The role of miRNA125b in the progression of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101712.
    >> Share

  232. LUO L, He X, Li K, Long Y, et al
    Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101581.
    >> Share

  233. YANG D, Wu H, Nong W, Zheng M, et al
    A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101509.
    >> Share

  234. DE SOUSA MAGALHAES R, Xavier S, Magalhaes J, Rosa B, et al
    Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101580.
    >> Share

  235. BOEKEN T, Gallois C, Douard R, Meatchi T, et al
    Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.
    Clin Res Hepatol Gastroenterol. 2021;45:101557.
    >> Share

    August 2021
  236. LARREY E, Cluzel P, Rudler M, Goumard C, et al
    (TIPS for patients with early HCC: a bridge to liver transplantation).
    Clin Res Hepatol Gastroenterol. 2021 Aug 13:101790.
    >> Share

  237. BOUZBIB C, El Mourabit H, Wendum D, Lasnier E, et al
    ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2021 Aug 9:101784.
    >> Share

    July 2021
  238. DUMORTIER J, Besch C, Moga L, Coilly A, et al
    NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.
    Clin Res Hepatol Gastroenterol. 2021 Jul 28:101774.
    >> Share

  239. VILLERET F, Dumortier J, Erard-Poinsot D
    How will NAFLD change the liver transplant landscape in the 2020s?
    Clin Res Hepatol Gastroenterol. 2021 Jul 23:101759.
    >> Share

  240. LANTHIER N, Starkel P, Dahlqvist G
    Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?
    Clin Res Hepatol Gastroenterol. 2021;45:101721.
    >> Share

  241. LIU W, Xu C, Meng Q, Kang P, et al
    The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101527.
    >> Share

  242. CAMPOS-MURGUIA A, Valdez-Hernandez P, Cordova-Gallardo J, Arteaga-Vazquez J, et al
    Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101519.
    >> Share

  243. KIM KM, Roh JH, Lee S, Yoon JH, et al
    Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
    Clin Res Hepatol Gastroenterol. 2021;45:101510.
    >> Share

  244. CAI L, Li H, Guo J, Zhao W, et al
    Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Clin Res Hepatol Gastroenterol. 2021;45:101535.
    >> Share

  245. SHI JY, Sun LY, Quan B, Xing H, et al
    A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101534.
    >> Share

  246. IM HJ, Ahn YC, Wang JH, Lee MM, et al
    Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.
    Clin Res Hepatol Gastroenterol. 2021;45:101526.
    >> Share

  247. PERRAULT F, Echelard P, Viens D, Borduas M, et al
    Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
    Clin Res Hepatol Gastroenterol. 2021;45:101475.
    >> Share

  248. LIU J, Dai XL, Zhou XJ, Gu BH, et al
    Metamizole-induced acute liver failure in a boy.
    Clin Res Hepatol Gastroenterol. 2021;45:101570.
    >> Share

  249. MOSCHOURI E, Hocquelet A, Vermersch M, Fraga M, et al
    DIPS, a safe and effective alternative in patients with unfavorable anatomy to TIPSS: first experience in a tertiary center.
    Clin Res Hepatol Gastroenterol. 2021;45:101715.
    >> Share

  250. COLAK Y, Hasan B, Erkalma B, Tandon K, et al
    Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.
    Clin Res Hepatol Gastroenterol. 2021;45:101710.
    >> Share

  251. ILUZ-FREUNDLICH D, Grubert Van Iderstine M, Uhanova J, Zhang M, et al
    Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis.
    Clin Res Hepatol Gastroenterol. 2021;45:101694.
    >> Share

    June 2021
  252. QU Y, Li T, Lin C, Liu F, et al
    Animal Naming Test for the Assessment of Minimal Hepatic Encephalopathy in Asian Cirrhotic Populations.
    Clin Res Hepatol Gastroenterol. 2021 Jun 3:101729.
    >> Share

  253. RAZAQ S, Kara M, Ozcakar L
    Measure Grip Strength, Gait Speed and Quadriceps Muscle in Cirrhosis. Comment to "Frailty, sarcopenia and mortality in cirrhosis: What is the best assessment, how to interpret the data correctly and what interventions are possible?"
    Clin Res Hepatol Gastroenterol. 2021 Jun 1:101727.
    >> Share

    May 2021
  254. VUJAKLIJA BRAJKOVIC A, Zlopasa O, Gubarev Vrdoljak N, Goran T, et al
    Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19.
    Clin Res Hepatol Gastroenterol. 2021;45:101678.
    >> Share

  255. SERRA F, Bonaduce I, De Ruvo N, Cautero N, et al
    Covid-19 and hepatic injury: A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101605.
    >> Share

  256. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
    HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
    Clin Res Hepatol Gastroenterol. 2021;45:101608.
    >> Share

  257. WORLAND T, O'Neill P, Rusli F
    Resolution of metastatic hepatocellular carcinoma with sour cherry intake.
    Clin Res Hepatol Gastroenterol. 2021;45:101663.
    >> Share

  258. DEVICTOR J, Leclercq A, Hazo JB, Burnet E, et al
    Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101650.
    >> Share

  259. MU X, Tong J, Xu X, Chen J, et al
    World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101548.
    >> Share

  260. ARAZ M, Kilinc F, Kerimoglu U, Keskin M, et al
    Irinotecan-induced NASH and liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101606.
    >> Share

  261. KALOGIROU MS, Patoulias D, Haidich AB, Akriviadis E, et al
    Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2021;45:101568.
    >> Share

  262. LIN M, Zeng H, Deng G, Lei J, et al
    Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101530.
    >> Share

  263. KARNSAKUL W, Wasuwanich P, Ingviya T, Laengvejkal P, et al
    Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2021;45:101549.
    >> Share

  264. KARATAS E, Bouchecareilh M
    Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101538.
    >> Share

  265. DE MUNCK TJI, Verhaegh P, Lodewick T, Bakers F, et al
    Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
    Clin Res Hepatol Gastroenterol. 2021;45:101500.
    >> Share

  266. DE VOS N, Van der Meulen J, Van Der Linden M, Claes K, et al
    Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101478.
    >> Share

  267. LYKAVIERIS P, Bernard O, Jacquemin E
    Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
    Clin Res Hepatol Gastroenterol. 2021;45:101472.
    >> Share

  268. RIVAS M, Aguiar T, Fernandes G, Lemes R, et al
    DNA methylation as a key epigenetic player for hepatoblastoma characterization.
    Clin Res Hepatol Gastroenterol. 2021;45:101684.
    >> Share

  269. BOILLOT O, Cayot B, Guillaud O, Crozet-Chaussin J, et al
    Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.
    Clin Res Hepatol Gastroenterol. 2021;45:101670.
    >> Share

  270. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
    Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101675.
    >> Share

  271. ZAREBSKA I, Gzil A, Durslewicz J, Jaworski D, et al
    The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.
    Clin Res Hepatol Gastroenterol. 2021;45:101664.
    >> Share

    April 2021
  272. OZCELIK F
    Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters.
    Clin Res Hepatol Gastroenterol. 2021 Apr 27:101708.
    >> Share

  273. CARDOSO CC, Matiollo C, Pereira CHJ, Fonseca JS, et al
    B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2021 Apr 11:101698.
    >> Share

    March 2021
  274. TORNAI D, Vitalis Z, Jonas A, Janka T, et al
    Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
    Clin Res Hepatol Gastroenterol. 2021;45:101579.
    >> Share

  275. CAO X, Cao Z, Ou C, Zhang L, et al
    Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101583.
    >> Share

  276. CORPECHOT C
    The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
    Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.
    >> Share

  277. ALTIERI M, Seree O, Lobbedez T, Segol P, et al
    Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101514.
    >> Share

  278. LANTHIER N, Starkel P, Dahlqvist G
    Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101661.
    >> Share

  279. COUPIER A, Pioche M, Steer N, Zoulim F, et al
    An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101662.
    >> Share

  280. BLANC JF, Debaillon-Vesque A, Roth G, Barbare JC, et al
    Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
    Clin Res Hepatol Gastroenterol. 2021;45:101590.
    >> Share

  281. TIAN J, Hu D
    LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
    Clin Res Hepatol Gastroenterol. 2021;45:101490.
    >> Share

  282. SOBOTKA LA, Chen JL, Wellner MR
    Compression induced hepatic injury: an unusual case of abnormal liver function tests.
    Clin Res Hepatol Gastroenterol. 2021;45:101655.
    >> Share

  283. LIU Y, Wu H, Wang Z, Wu J, et al
    Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
    Clin Res Hepatol Gastroenterol. 2021;45:101312.
    >> Share

  284. SU Q, Wang H
    Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.
    Clin Res Hepatol Gastroenterol. 2021;45:101648.
    >> Share

  285. ROSSO C, Caviglia GP, Armandi A, Ribaldone DG, et al
    Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2021;45:101611.
    >> Share

  286. XIE Z, Wu Y, Liu S, Lai Y, et al
    LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis.
    Clin Res Hepatol Gastroenterol. 2021;45:101469.
    >> Share

  287. MAZZOLA A, Magro B, Perdigao F, Charlotte F, et al
    Acute liver failure and HELLP syndrome: A clinical case and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101498.
    >> Share

  288. SHEN X, Huang Y, Guo H, Peng H, et al
    Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
    Clin Res Hepatol Gastroenterol. 2021;45:101495.
    >> Share

  289. XU X, Hou Z, Xu Y, Gu H, et al
    The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101482.
    >> Share

  290. CHEN C, Qiu H, Yao Y, Zhang Z, et al
    Comprehensive predictive factors for CalliSpheres(R) microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101460.
    >> Share

  291. TURPIN A, de Baere T, Heurgue A, Le Malicot K, et al
    Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101464.
    >> Share

    February 2021
  292. GAO Y, Liu H, Tang F, Zhang X, et al
    Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021 Feb 15:101649.
    >> Share

    January 2021
  293. ZHAO N, Liu X, Guo H, Zhao X, et al
    Interleukin-35: An emerging player in the progression of liver diseases.
    Clin Res Hepatol Gastroenterol. 2021;45:101518.
    >> Share

  294. CHARPY F, Debourdeau A, Boivineau L, Meszaros M, et al
    Hepatic amyloidosis as a case of fatal fulminant liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101506.
    >> Share

  295. BRAUNER C, Joveleviths D, Alvares-da-Silva MR
    Hepatotoxicity by methyl methacrylate.
    Clin Res Hepatol Gastroenterol. 2021;45:101513.
    >> Share

  296. THEVENOT T, Savale L, Sitbon O
    Portopulmonary hypertension: An unfolding story.
    Clin Res Hepatol Gastroenterol. 2021;45:101492.
    >> Share

  297. WANG J, Feng L, Zhang L
    Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101440.
    >> Share

  298. LEMAITRE C, Thiebaut PA, Francois A, Michel P, et al
    An unexpected cause of heterogeneous liver.
    Clin Res Hepatol Gastroenterol. 2021;45:101444.
    >> Share

  299. KANG Y, Park S, Kim S, Han SJ, et al
    Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
    Clin Res Hepatol Gastroenterol. 2021;45:101437.
    >> Share

  300. RAFFETTI E, Portolani N, Molfino S, Mentasti S, et al
    Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.
    Clin Res Hepatol Gastroenterol. 2021;45:101433.
    >> Share

  301. CHANG Y, He J, Xiang X, Li H, et al
    LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101435.
    >> Share

    November 2020
  302. HUANG C, Seah JJ, Tan CK, Kam JW, et al
    Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Nov 29:101528.
    >> Share

    August 2020
  303. ELKRIEF L, Houssel-Debry P, Ackermann O, Franchi-Abella S, et al
    Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction.
    Clin Res Hepatol Gastroenterol. 2020 Aug 17. pii: S2210-7401(20)30091.
    >> Share

    July 2020
  304. TRIPON S, Mayer P, Svab A, Habersetzer F, et al
    Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Jul 9. pii: S2210-7401(20)30181.
    >> Share

    April 2020
  305. ABERGEL A, Gasperment M, Nery FG, Buchard B, et al
    Extrahepatic portal vein obstruction (EHPVO) in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Apr 17. pii: S2210-7401(20)30089.
    >> Share

  306. JANKOWSKA I, Czubkowski P, Rokicki D, Lipinski P, et al
    Acute liver failure due to DGUOK deficiency-is liver transplantation justified?
    Clin Res Hepatol Gastroenterol. 2020 Apr 8. pii: S2210-7401(20)30082.
    >> Share

    March 2020
  307. FELLI E, Baumert T, Pessaux P
    Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
    Clin Res Hepatol Gastroenterol. 2020 Mar 18. pii: S2210-7401(20)30049.
    >> Share

  308. MORANDEAU E, Rayer C, Jezequel C, Guyader D, et al
    Hepatic encephalopathy post liver transplantation.
    Clin Res Hepatol Gastroenterol. 2020 Mar 10. pii: S2210-7401(20)30039.
    >> Share

    January 2020
  309. PETA V, Zhu J, Lubman DM, Huguet S, et al
    Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
    >> Share

  310. HEDJOUDJE A, Cervoni JP, Patry C, Chatot M, et al
    Takotsubo cardiomyopathy triggered by delirium tremens in a cirrhotic patient with acute-on-chronic liver failure: A case report.
    Clin Res Hepatol Gastroenterol. 2020 Jan 9. pii: S2210-7401(19)30262.
    >> Share

    November 2019
  311. ALLAIRE M, Cadranel JF, Nguyen TTN, Garioud A, et al
    Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
    Clin Res Hepatol Gastroenterol. 2019 Nov 6. pii: S2210-7401(19)30224.
    >> Share

    October 2019
  312. ALLAIRE M, Walter A, Sutter O, Nahon P, et al
    TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
    Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217.
    >> Share

    June 2019
  313. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
    Primary biliary cholangitis in patients with inflammatory bowel disease.
    Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016